Disruption of androgen receptor function inhibits proliferation of androgen-refractory prostate cancer cells

Ofelia L. Zegarra-Moro, Lucy J. Schmidt, Haojie Huang, Donald J. Tindall

Research output: Contribution to journalArticle

355 Citations (Scopus)

Abstract

Prostate cancer cells depend on androgens and the androgen receptor (AR) for survival. However, after androgen ablation therapy, tumors relapse to an androgen-refractory state. To determine whether the androgen receptor is critical for proliferation of androgen-refractory prostate cancer cells, we disrupted the activity of the androgen receptor with an antibody and an AR mRNA hammerhead ribozyme in the following cell lines: LNCaP (androgen-sensitive), LNCaP-Rf and LNCaP-C4 (androgen-refractory), and DU-145 (androgen-insensitive). Microinjection of either antibody or ribozyme inhibited proliferation of androgen-refractory cells. These findings demonstrate that the AR is critical for proliferation of androgen-refractory cells, even in the absence of androgens.

Original languageEnglish (US)
Pages (from-to)1008-1013
Number of pages6
JournalCancer Research
Volume62
Issue number4
StatePublished - 2002

Fingerprint

Androgen Receptors
Androgens
Prostatic Neoplasms
Catalytic RNA
Antibodies
Microinjections
Recurrence
Cell Line
Messenger RNA

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Disruption of androgen receptor function inhibits proliferation of androgen-refractory prostate cancer cells. / Zegarra-Moro, Ofelia L.; Schmidt, Lucy J.; Huang, Haojie; Tindall, Donald J.

In: Cancer Research, Vol. 62, No. 4, 2002, p. 1008-1013.

Research output: Contribution to journalArticle

Zegarra-Moro, Ofelia L. ; Schmidt, Lucy J. ; Huang, Haojie ; Tindall, Donald J. / Disruption of androgen receptor function inhibits proliferation of androgen-refractory prostate cancer cells. In: Cancer Research. 2002 ; Vol. 62, No. 4. pp. 1008-1013.
@article{89fda2564da9408e81c94ee65c6d8cc2,
title = "Disruption of androgen receptor function inhibits proliferation of androgen-refractory prostate cancer cells",
abstract = "Prostate cancer cells depend on androgens and the androgen receptor (AR) for survival. However, after androgen ablation therapy, tumors relapse to an androgen-refractory state. To determine whether the androgen receptor is critical for proliferation of androgen-refractory prostate cancer cells, we disrupted the activity of the androgen receptor with an antibody and an AR mRNA hammerhead ribozyme in the following cell lines: LNCaP (androgen-sensitive), LNCaP-Rf and LNCaP-C4 (androgen-refractory), and DU-145 (androgen-insensitive). Microinjection of either antibody or ribozyme inhibited proliferation of androgen-refractory cells. These findings demonstrate that the AR is critical for proliferation of androgen-refractory cells, even in the absence of androgens.",
author = "Zegarra-Moro, {Ofelia L.} and Schmidt, {Lucy J.} and Haojie Huang and Tindall, {Donald J.}",
year = "2002",
language = "English (US)",
volume = "62",
pages = "1008--1013",
journal = "Journal of Cancer Research",
issn = "0099-7013",
publisher = "American Association for Cancer Research Inc.",
number = "4",

}

TY - JOUR

T1 - Disruption of androgen receptor function inhibits proliferation of androgen-refractory prostate cancer cells

AU - Zegarra-Moro, Ofelia L.

AU - Schmidt, Lucy J.

AU - Huang, Haojie

AU - Tindall, Donald J.

PY - 2002

Y1 - 2002

N2 - Prostate cancer cells depend on androgens and the androgen receptor (AR) for survival. However, after androgen ablation therapy, tumors relapse to an androgen-refractory state. To determine whether the androgen receptor is critical for proliferation of androgen-refractory prostate cancer cells, we disrupted the activity of the androgen receptor with an antibody and an AR mRNA hammerhead ribozyme in the following cell lines: LNCaP (androgen-sensitive), LNCaP-Rf and LNCaP-C4 (androgen-refractory), and DU-145 (androgen-insensitive). Microinjection of either antibody or ribozyme inhibited proliferation of androgen-refractory cells. These findings demonstrate that the AR is critical for proliferation of androgen-refractory cells, even in the absence of androgens.

AB - Prostate cancer cells depend on androgens and the androgen receptor (AR) for survival. However, after androgen ablation therapy, tumors relapse to an androgen-refractory state. To determine whether the androgen receptor is critical for proliferation of androgen-refractory prostate cancer cells, we disrupted the activity of the androgen receptor with an antibody and an AR mRNA hammerhead ribozyme in the following cell lines: LNCaP (androgen-sensitive), LNCaP-Rf and LNCaP-C4 (androgen-refractory), and DU-145 (androgen-insensitive). Microinjection of either antibody or ribozyme inhibited proliferation of androgen-refractory cells. These findings demonstrate that the AR is critical for proliferation of androgen-refractory cells, even in the absence of androgens.

UR - http://www.scopus.com/inward/record.url?scp=0036170838&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036170838&partnerID=8YFLogxK

M3 - Article

C2 - 11861374

AN - SCOPUS:0036170838

VL - 62

SP - 1008

EP - 1013

JO - Journal of Cancer Research

JF - Journal of Cancer Research

SN - 0099-7013

IS - 4

ER -